K2M Group Holdings Inc (NASDAQ:KTWO) insider John Philip Md Kostuik sold 1,090 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $24.08, for a total value of $26,247.20. Following the transaction, the insider now directly owns 201,961 shares in the company, valued at $4,863,220.88. The sale was disclosed in a document filed with the SEC, which is available at this link.

John Philip Md Kostuik also recently made the following trade(s):

  • On Thursday, May 25th, John Philip Md Kostuik sold 50,000 shares of K2M Group Holdings stock. The shares were sold at an average price of $22.70, for a total value of $1,135,000.00.

K2M Group Holdings Inc (NASDAQ:KTWO) traded down 0.021% during trading on Wednesday, reaching $24.045. The company had a trading volume of 377,686 shares. The company’s market capitalization is $1.04 billion. The firm’s 50 day moving average is $24.04 and its 200 day moving average is $21.99. K2M Group Holdings Inc has a one year low of $15.45 and a one year high of $25.99.

K2M Group Holdings (NASDAQ:KTWO) last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. K2M Group Holdings had a negative return on equity of 14.26% and a negative net margin of 13.79%. The business had revenue of $65.70 million for the quarter, compared to the consensus estimate of $66.26 million. During the same period in the prior year, the business posted ($0.27) earnings per share. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. On average, equities research analysts predict that K2M Group Holdings Inc will post ($0.78) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/16/k2m-group-holdings-inc-ktwo-insider-john-philip-md-kostuik-sells-1090-shares.html.

Large investors have recently modified their holdings of the stock. IBM Retirement Fund bought a new stake in shares of K2M Group Holdings during the first quarter worth about $2,677,000. JPMorgan Chase & Co. increased its stake in shares of K2M Group Holdings by 54.3% in the first quarter. JPMorgan Chase & Co. now owns 1,409,360 shares of the medical device company’s stock worth $28,906,000 after buying an additional 495,749 shares during the period. Nicholas Company Inc. increased its stake in shares of K2M Group Holdings by 6.6% in the first quarter. Nicholas Company Inc. now owns 253,865 shares of the medical device company’s stock worth $5,206,000 after buying an additional 15,625 shares during the period. Credit Suisse AG increased its stake in shares of K2M Group Holdings by 9.8% in the first quarter. Credit Suisse AG now owns 212,672 shares of the medical device company’s stock worth $4,360,000 after buying an additional 18,931 shares during the period. Finally, Parkwood LLC bought a new stake in shares of K2M Group Holdings during the first quarter worth about $223,000. Institutional investors and hedge funds own 98.55% of the company’s stock.

A number of equities analysts recently weighed in on the company. Royal Bank Of Canada reissued a “buy” rating on shares of K2M Group Holdings in a report on Wednesday, May 3rd. Zacks Investment Research raised K2M Group Holdings from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Cowen and Company reissued a “buy” rating and set a $26.00 price objective on shares of K2M Group Holdings in a report on Wednesday, July 19th. Barclays PLC raised their price objective on K2M Group Holdings from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, April 24th. Finally, Oppenheimer Holdings, Inc. set a $26.00 price objective on K2M Group Holdings and gave the company a “buy” rating in a report on Wednesday, May 3rd. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. K2M Group Holdings has a consensus rating of “Buy” and an average price target of $26.25.

About K2M Group Holdings

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Insider Buying and Selling by Quarter for K2M Group Holdings (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.